Zenas BioPharma, Inc.
For the period ended Oct 12, 2026. Filed Oct 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 12, 2026 · Filed Oct 13, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Phase 3 INDIGO Open-Label Extension Data
Phase 3 INDIGO Open-Label Extension Data
Participants who completed the 52-week randomized, controlled period of the Phase 3 INDIGO study could enter the open-label extension and receive 250 mg obexelimab subcutaneously once weekly. The open-label extension evaluated longer-term flare protection and safety of continued obexelimab treatment in patients with IgG4-RD.
| · | The 12-month probability of remaining flare-free was 0.93 based upon investigator- and adjudication committee-confirmed flares requiring rescue therapy, and 0.87 based upon investigator-determined flares requiring rescue therapy, with five patients pending adjudication at the time of the data cutoff. |
| · | The median and mean cumulative glucocorticoid rescue doses were 0 mg and 105 mg, respectively. |
| · | Adverse event rates were comparable to or lower than those observed during the randomized, controlled period. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.